COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety.
Nat Rev Clin Oncol
; 19(6): 385-401, 2022 06.
Article
in English
| MEDLINE | ID: covidwho-1740445
ABSTRACT
Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and associated mortality than the general population. Owing to this increased risk, patients with cancer have been prioritized for COVID-19 vaccination globally, for both primary and booster vaccinations. However, given that these patients were not included in the pivotal clinical trials, considerable uncertainty remains regarding vaccine efficacy, and the extent of humoral and cellular immune responses in these patients, as well as the risks of vaccine-related adverse events. In this Review, we summarize the current knowledge generated in studies conducted since COVID-19 vaccines first became available. We also highlight critical points that might affect vaccine efficacy in patients with cancer in the future.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19 Vaccines
/
COVID-19
/
Neoplasms
Type of study:
Prognostic study
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Nat Rev Clin Oncol
Journal subject:
Neoplasms
Year:
2022
Document Type:
Article
Affiliation country:
S41571-022-00610-8
Similar
MEDLINE
...
LILACS
LIS